NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG

IPX054 100 mg

IPX054 containing 25 mg carbidopa and 100 mg levodopa

DRUG

IPX054 150 mg

IPX054 containing 37.5 mg carbidopa and 150 mg levodopa

DRUG

IPX054 200 mg

CD-LD CR containing 50 mg carbidopa and 200 mg levodopa

DRUG

IPX054 250 mg

CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa

DRUG

IPX054 300 mg

CD-LD CR containing 75 mg carbidopa and 300 mg levodopa

Trial Locations (2)

Site 102, Lawrence

Site 101, Sunnyvale